文献速递肝病消化道肿瘤与早癌

FYN/LCK激酶平衡调控肝癌前体耗竭T细胞分化

FYN/LCK kinase balance as a metabolic switch orchestrates progenitor-exhausted T-cell differentiation in hepatocellular carcinoma.
PubMed 文献 · Hepatology · 2026-03-11

该研究通过整合肝癌单细胞RNA测序数据构建耗竭CD8+T细胞图谱,发现FYN是免疫检查点阻断应答者中前体耗竭T细胞的标志物。FYN缺失导致LCK过度活化,通过增强糖酵解和损害线粒体功能破坏代谢稳态,驱动终末耗竭。短暂抑制LCK可恢复FYN活性、维持前体耗竭T细胞干性,并在临床前模型中增强过继细胞治疗和抗PD-1疗效。

要点

  • FYN是肝癌免疫检查点阻断应答者前体耗竭T细胞的标志物
  • FYN缺失致LCK过度活化,通过代谢重编程驱动终末耗竭
  • 短暂抑制LCK可维持前体耗竭T细胞干性并增强免疫治疗疗效

核心结论

  • FYN/LCK激酶平衡通过代谢重编程调控前体耗竭T细胞的终末耗竭,调节该平衡是克服肝癌免疫治疗耐药的潜在策略。

研究设计与样本

  • 整合分析肝癌单细胞RNA测序数据集构建耗竭CD8+T细胞图谱,并结合临床前肝癌模型进行机制与干预验证。

主要发现

  • FYN被鉴定为免疫检查点阻断应答者中前体耗竭T细胞的标志物。
  • CD8+T细胞中FYN缺失诱导LCK过度活化,在高亲和力抗原刺激下驱动终末耗竭。
  • LCK过度活化通过触发过度糖酵解和损害线粒体功能破坏前体耗竭T细胞代谢稳态。
  • 抑制LCK可提升代偿性FYN活性、恢复线粒体适应性并保留前体耗竭T细胞干性。
  • 临床前模型中T细胞扩增期短暂抑制LCK或抗PD-1治疗前低剂量抑制LCK均改善疗效。

临床怎么用

  • 在肝癌免疫治疗中可考虑将FYN/LCK激酶平衡作为克服免疫检查点阻断耐药的潜在干预靶点。
  • T细胞扩增期短暂抑制LCK可能提升过继细胞治疗中前体耗竭T细胞的持久性与干性。
  • 抗PD-1治疗前预防性低剂量抑制LCK可能扩增前体耗竭T细胞池并减少终末耗竭。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Immune checkpoint blockade (ICB) shows therapeutic promise in hepatocellular carcinoma (HCC) but is associated with suboptimal responses in patients. Progenitor-exhausted T (Tpex) cells are key responders to ICB, but the regulatory mechanisms governing Tpex maintenance in HCC remain elusive. APPROACH AND RESULTS: Through an integrated analysis of HCC single-cell RNA-sequencing datasets, we constructed an exhausted CD8 + T-cell atlas and identified the kinase FYN as a marker of Tpex cells in ICB responders. FYN deficiency in CD8 + T cells induced LCK hyperactivation, which drove terminal exhaustion under high-affinity antigen stimulation. Mechanistically, LCK hyperactivation disrupted metabolic homeostasis by triggering excessive glycolysis and impairing mitochondrial function in Tpex cells. Conversely, LCK inhibition elevated compensatory FYN activity, restored mitochondrial fitness, and preserved Tpex cell stemness. In preclinical HCC models, transient LCK inhibition during T-cell expansion enhanced adoptive cell therapy efficacy by increasing Tpex cell persistence and stemness. Additionally, preemptive low-dose LCK inhibition before anti-PD-1 therapy expanded the Tpex cell pool, reduced terminal exhaustion, and improved therapeutic outcomes. CONCLUSIONS: This study establishes the FYN/LCK balance as a critical regulator of the terminal exhaustion of Tpex cells through metabolic reprogramming. These findings suggest that modulating the FYN/LCK kinase balance is a promising strategy to overcome immunotherapy resistance in HCC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Wu J, Jiang Z, Li Q, et al. FYN/LCK kinase balance as a metabolic switch orchestrates progenitor-exhausted T-cell differentiation in hepatocellular carcinoma. Hepatology. 2026. PMID: 41812035. doi:10.1097/HEP.0000000000001740

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。